MINNEAPOLIS, March 6, 2017 /PRNewswire/ -- Cogentix
Medical, Inc. (NASDAQ: CGNT), a medical device company that
develops, manufactures and markets innovative proprietary products
for the urology market, today announced that the Company will
participate in the 29th Annual ROTH Conference on Monday, March 13, 2017 and Tuesday, March 14, 2017. Darin Hammers, President and CEO, and
Brett Reynolds, CFO will be
available to meet with investors one-on-one at the conference and
will make a presentation at the conference.
On Monday, March 13, 2017
management will present at 7:00 a.m. Pacific
Time (9:00 a.m. Central Time)
at the Ritz Carlton in Dana Point,
CA. A live webcast of the presentation will be available on
the investor section of the Company's website at
ir.cogentixmedical.com under "Events & Presentations."
A replay of the webcast will also be available on the Company's
website following the event.
As a reminder, the Company will issue its fourth quarter
financial results before the market open this Thursday, March 9, 2017 followed by a conference
call and webcast to discuss the financial results the same day at
11:00 a.m. Eastern Time (10:00 a.m. Central Time).
About Cogentix Medical
Cogentix Medical, Inc.,
headquartered in Minnetonka,
Minnesota, with additional operations in New York, Massachusetts, The
Netherlands and the United
Kingdom, is a global medical device company. We
design, develop, manufacture and market products for flexible
endoscopy with our unique product lines featuring a streamlined
visualization system and proprietary sterile disposable microbial
barrier, known as PrimeSight™, providing users with efficient and
cost effective endoscope turnover while enhancing patient safety.
We also commercialize the Urgent® PC Neuromodulation System, an
FDA-cleared device that delivers percutaneous tibial nerve
stimulation (PTNS) for the office-based treatment of overactive
bladder (OAB). OAB is a chronic condition that affects
approximately 42 million U.S. adults. The symptoms include urinary
urgency, frequency and urge incontinence. We also offer
Macroplastique®, an injectable urethral bulking agent for the
treatment of adult female stress urinary incontinence primarily due
to intrinsic sphincter deficiency. For more information on Cogentix
Medical and our products, please visit us at
www.cogentixmedical.com. 'CGNT-G'
For Further Information:
Cogentix Medical, Inc.
Brett Reynolds, SVP and CFO
952-426-6152
EVC Group
Doug Sherk/Brian Moore (Investors)
415-652-9100/310-579-6199
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cogentix-medical-to-participate-in-the-29th-annual-roth-conference-300417990.html
SOURCE Cogentix Medical, Inc.